Results 271 to 280 of about 234,058 (316)
Some of the next articles are maybe not open access.
Active Specific Immunotherapy Against Adenocarcinomas
Cancer Investigation, 1994(1994). Active Specific Immunotherapy Against Adenocarcinomas. Cancer Investigation: Vol. 12, No. 1, pp. 46-56.
G D, MacLean +4 more
openaire +2 more sources
Active specific immunotherapy for colorectal cancer
Expert Review of Anticancer Therapy, 2003With advances in molecular biology and the identification of tumor-associated antigens, a number of new strategies have been developed in an attempt to overcome the limits of chemotherapy and to aid in the fight to cure patients of metastatic and micrometastatic colorectal carcinomas.
Adrian A, Indar +1 more
openaire +2 more sources
Venom immunotherapy induces monocyte activation
Clinical & Experimental Allergy, 2001Background Venom immunotherapy (VIT) is an efficient treatment of hymenoptera venom allergy. The mechanism of VIT is based on the induction of tolerance of allergen‐specific Th2 cells. The mechanisms of this T cell modulation are unknown, and could depend on cytokines produced by other cell types such as interleukin (IL)‐12, tumour necrosis factor (TNF)
A, Magnan +6 more
openaire +2 more sources
Active Immunotherapy by B.C.G.
1971Immunotherapy is a new method of killing malignant cells in the treatment of cancer. It is well known, from the rejection of incompatible grafts, that membrane antigens can excite an immune reaction capable of killing cells carrying these antigens. It is also known that these immune reactions can sometimes fail to kill the cells that have raised the ...
G. Mathe +3 more
openaire +1 more source
Active Specific Immunotherapy in Ovarian Cancer
1979The rationale of any programme of active specific immunotherapy depends on the demonstration of appropriate tumour-directed, cell-mediated immune responses, and agents designed to manipulate these immunological responses must be shown to have some therapeutic effect.
M E, Crowther +5 more
openaire +2 more sources
Active specific immunotherapy in malignant melanoma
Seminars in Surgical Oncology, 1989AbstractWe have recently initiated clinical trials of active specific immunotherapy evaluating a new polyvalent melanoma cell vaccine in patients with high‐risk and/or recurrent melanoma. The vaccine has been administered alone, or in combination with low‐dose cyclophosphamide, as an immunomodulator of suppressor cells. Cyclophosphamide is effective in
D L, Morton +6 more
openaire +2 more sources
Personalized approaches to active immunotherapy in cancer
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2016Immunotherapy is emerging as a promising anti-cancer curative modality. However, in contrast to recent advances obtained employing checkpoint blockade agents and T cell therapies, clinical efficacy of therapeutic cancer vaccines is still limited. Most vaccination attempts in the clinic represent "off-the shelf" approaches since they target common "self"
Ophir E +4 more
openaire +3 more sources
Active and passive immunotherapy: vaccines and antibodies
BJU International, 2007Contains fulltext : 52701.pdf (Publisher’s version ) (Closed access)
Oosterwijk, E. +2 more
openaire +3 more sources
Active Specific Immunotherapy in Colon Cancer
2005Colorectal cancer is one of the leading causes of cancer-related mortality. After a series of clinical trials, the adjuvant 5-FU-based chemotherapy has established a definitive role in the management of stage III colon cancer. While the precise role for chemotherapy in stage II disease remains under investigation, less toxic treatment modalities such ...
openaire +2 more sources
1976
When we started the first clinical controlled trial or active immunotherapy in 1963 (MATHS et al., 1968, 1969a), the favourable tumour growth plate of the immune balance was not known. Nevertheless, it appeared reasonable to conduct experiments on active immunotherapy of experimental established tumours, and to apply them to man in the conditions and ...
openaire +1 more source
When we started the first clinical controlled trial or active immunotherapy in 1963 (MATHS et al., 1968, 1969a), the favourable tumour growth plate of the immune balance was not known. Nevertheless, it appeared reasonable to conduct experiments on active immunotherapy of experimental established tumours, and to apply them to man in the conditions and ...
openaire +1 more source